Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis

Sudhir Kumar Yadav, Devika Soin, Kouichi Ito, Suhayl Dhib-Jalbut

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Dimethyl fumarate (DMF) is an oral, disease-modifying agent for the treatment of relapsing–remitting multiple sclerosis (RRMS). However, details regarding its mode of action are still emerging. It is believed that the mode of action of DMF involves both nuclear factor erythroid-derived 2-related factor (Nrf2)–dependent and independent pathways, which lead to an anti-inflammatory immune response due to type II myeloid cell and Th2 cell differentiation and neuroprotection. In this review, we will focus on the molecular and signaling effects of DMF that lead to changes in peripheral immune cell composition and function, alteration in CNS cell-specific functions, and effect on the blood-brain barrier.

Original languageEnglish (US)
Pages (from-to)463-472
Number of pages10
JournalJournal of Molecular Medicine
Issue number4
StatePublished - Apr 12 2019

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)


  • Dimethyl fumarate
  • Immunomodulation
  • Neuroprotection
  • Nuclear factor erythroid-derived 2-related factor
  • Relapsing–remitting multiple sclerosis

Fingerprint Dive into the research topics of 'Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis'. Together they form a unique fingerprint.

Cite this